Demi

Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Society's Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Jun 6, 2007 - Metabasis Therapeutics,Inc. (Nasdaq:MBRX), a biopharmaceutical company focused on thediscovery, development and commercialization of novel drugs for thetreatment of metabolic and liver diseases by applying uniquecapabilities for targeting the liver and liver pathways, announcedtoday that two posters were presented at the Endocrine Society's89th Annu...

Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal Challenge of Live Virus, Pre-Clinical Data Show

Study Presented at Second International Conference on AvianInfluenza at France's Pasteur Institute PARIS, June 01, 2007 /PRNewswire-FirstCall/ -- Very low doses ofNovavax Inc.'s pandemic influenza vaccine provided protectionagainst a lethal challenge of live H5N1 viruses, according topre-clinical data presented here today at the Second InternationalConference on Avian Influenza in Humans....

VGX Pharmaceuticals' Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models

MALAGA, Spain--(BUSINESS WIRE)--May 23, 2007 - VGX Pharmaceuticals'novel pandemic influenza vaccine candidates triggered protectiveimmune responses in pre-clinical challenge studies, according todata presented for the first time today at the Third InternationalConference on DNA Vaccines in Malaga, Spain. VGX scientists created four synthetic consensus DNA vaccines toprotect against a leth...

Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric Academic Societies' Annual Meeting

Surfaxin Phase 2 BPD Clinical Data Selected and Presented asPlatform Presentation Aerosurf Utilizing Chrysalis Aerosol-Generator TechnologyDemonstrates Optimal Functional Activity WARRINGTON, Pa., May 8, 2007 (PRIME NEWSWIRE) -- DiscoveryLaboratories, Inc. (Nasdaq:DSCO) announced that results from itspreviously completed Phase 2 clinical trial of Surfaxin(r)(lucinactant intr...

Novavax Reports Positive Pre-Clinical Study Results from Live Virus Challenge to Pandemic Flu Vaccine

Ferret Study to be Part of Data Package Required to Begin ClinicalTrials ROCKVILLE, Md., May 03, 2007 /PRNewswire-FirstCall/ -- NovavaxInc. said today that it has received positive study results from alive virus challenge to ferrets inoculated with its pandemicinfluenza vaccine, paving the way for clinical trials to begin onschedule later this year. In the study, ferrets were inocu...

Pediatric Academic Societies' Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV

GAITHERSBURG, Md., May 2 /PRNewswire-FirstCall/ -- MedImmune, Inc.(Nasdaq: MEDI) today announced that seven abstracts will bepresented at the 2007 Pediatric Academic Societies' (PAS) AnnualMeeting demonstrating the company's commitment to advancing thescience of pediatric medicine. Data are from studies pertaining toMedImmune's approved and development-stage products, including bothmonoclon...

Rapid Response was Crucial to Containing the 1918 Flu Pandemic

BETHESDA, Md., April 2, 2007--One of the persistent riddles of thedeadly 1918 Spanish influenza pandemic is why it struck differentcities with varying severity. Why were some municipalities such asSt. Louis spared the fate of the hard-hit cities like Philadelphiawhen both implemented similar public health measures? What made t...

Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine

DEERFIELD, Ill., March 29, 2007 /PRNewswire-FirstCall/ -- BaxterInternational Inc. today announced final Phase I/II data for itsadjuvant-free investigational pandemic H5N1 influenza vaccine andplans to initiate a Phase III clinical trial of the candidatevaccine in Europe to confirm the study results. The Phase I/II study indicated that Baxter's H5N1 candidatevaccine is highly immun...